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Abstract
 Vitamin D plays an important role in brain development inIntroduction:
experimental studies; however, the effect of vitamin D deficiency on child
development remains inadequately characterized. We aimed to estimate
the effects of vitamin D deficiency on neurobehavioural outcomes in
children up to 18 years of age.
 We searched PubMed, EMBASE, PsycINFO, Scopus, CochraneMethods:
Library, Web of Science and Open Grey for published studies up to 10th
January 2020. We included all studies that assessed the effects of maternal
or child vitamin D status or vitamin D supplementation on neurobehavioural
outcomes in children. Study findings were synthesized qualitatively as the
high level of heterogeneity in study populations and methodologies
precluded a quantitative meta-analysis.
 Our search identified 5,633 studies, of which 31 studies withResults:
31,375 participants from 18 countries were included in the systematic
review. Of the studies identified, one was a randomised controlled trial
(RCT) of vitamin D supplementation in children, while 30 were
observational. The RCT (n=55) reported a beneficial effect of
supplementation with lower doses compared to higher doses of vitamin D
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 Any reports and responses or comments on the
article can be found at the end of the article.
supplementation with lower doses compared to higher doses of vitamin D
on motor development. Twelve mother-child studies (n=17,136) and five
studies in children (n=1,091) reported an association between low maternal
or child 25-hydroxyvitamin D levels and impaired neurobehavioural
outcomes in children, while 15 mother-child studies (n=20,778) and eight
studies in children (n=7,496) reported no association.
 Although animal studies point to an effect of vitamin DConclusions:
deficiency on brain development, there are few studies on the effects of
vitamin D deficiency on neurobehavioural outcomes in children and their
findings are inconsistent. There is a need for well-conducted, adequately
powered studies to further determine these effects in children.
 PROSPERO ID  ; registered on 15Registration: CRD42018087619
February 2018.
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Introduction
Impaired neurobehavioural outcomes are common among 
children worldwide, especially in low- and middle-income 
countries (LMICs)1. Approximately 81 million children below 
the age of five years have impaired cognitive and socioemotional 
development in LMICs globally and 44% of these children 
live in sub-Saharan Africa2. Impaired child development is 
associated with poor educational achievement and subsequent 
poverty and poor health outcomes3. Risk factors for impaired 
development include home environments lacking in stimulation, 
infections, malnutrition and micronutrient deficiencies3,4. Vitamin 
D deficiency and/or insufficiency is an important public health 
concern that affects approximately one billion people globally5,6. 
Evidence suggests that vitamin D deficiency is particularly 
widespread among children worldwide7–9.
Vitamin D may be important for brain development, especially 
in the early years of life when the brain is developing rapidly 
and is sensitive to nutrient deficiencies10. Animal and in vitro stud-
ies provide consistent evidence for an important role of vitamin D 
in brain development. Evidence includes indication of vita-
min D signalling in the brain, including presence of vitamin D 
receptors (VDR), metabolites and enzymes responsible for 
            Amendments from Version 1
We have revised the manuscript to address the comments and 
suggestions made by the reviewers.
1. We added the subheadings “Reporting guidelines” to the first 
paragraph in the methods section and “Study selection” to the first 
paragraph in the results section.
2. We have included a sub-section in the results section comparing 
studies that assessed development during infancy and those that 
assessed development in older children and have added more 
information on confounding in the discussion section. Results 
suggested that associations between maternal 25(OH)D levels and 
neurobehavioural outcomes were more likely to be observed in infants 
compared to children over one year old.
3. As suggested, we have excluded the randomised controlled trial 
by Salas et al., 2018 which included extremely preterm neonates, a 
group with a higher risk of neurodevelopmental delays compared to 
children born at full term. We have also updated Figure 1, Figure 2 and 
Extended datafile 2 to reflect this exclusion.
4. We have now added information on the different assays used 
to quantify serum or plasma 25(OH)D levels in Table 1 and also a 
summary of the teams that assessed neurobehavioural outcomes in 
the different studies.
5. Lastly, although high heterogeneity between studies precluded 
formal sensitivity analyses we compared study findings based on 
when 25(OH)D levels were measured, assays used to measure 
25(OH)D levels, definition for vitamin D status and tools used to assess 
neurobehavioural outcomes. We did not find any marked changes 
in the results based on 25(OH)D assays or definition for vitamin D 
status. Comparison of study findings based on neuroassessment tools 
was limited since most studies used a wide variety of tools to assess 
several neurobehavioural outcomes.
Any further responses from the reviewers can be found at the 
end of the article
REVISED
vitamin D activation and inactivation11,12. Furthermore, animal 
studies show that vitamin D is important for neuronal differentia-
tion and reducing apoptosis in the hippocampus, an area that is 
involved in language and memory13,14. Vitamin D is also important 
for neuroprotection and anti-inflammatory effects in the brain15,16 
(Figure 1). However, there are few epidemiological studies 
that have evaluated the effects of maternal or child vitamin D 
status on neurobehavioural outcomes.
In this systematic literature review, our objective was to estimate 
the effects of vitamin D deficiency and/or vitamin D supplemen-
tation on neurobehavioural outcomes in children. The outcomes 
of interest included cognitive and motor development, behav-
iour, intelligence, memory, school achievement and language. 
We further discuss the possible mechanisms by which vitamin D 
deficiency might influence child development from in vitro and 
animal studies.
Methods
Reporting guidelines
We used the Preferred Reporting Items for Systematic Review 
and Meta-analysis (PRISMA) guidelines17,18 and the Centre for 
Reviews and Dissemination (CRD) recommendations for under-
taking reviews in healthcare19. We registered the protocol on the 
PROSPERO database (registration number CRD42018087619).
Search strategy and eligibility criteria
We searched PubMed, EMBASE, PsycINFO, Scopus, Cochrane 
Library and Web of Science for relevant studies published up 
to 10th January 2020 without geographical or language limita-
tions. We also searched the Open Grey database for unpublished 
studies. We further scanned reference lists of identified studies 
and previous systematic reviews for relevant studies. We applied a 
search strategy combining Medical Subject Heading terms 
for [vitamin D] AND [neurobehavioural outcomes] AND 
[children] and modified the search strategy as appropriate for 
each of the specific databases (Extended data, file 1)18.
We included studies if they (i) involved participants below 18 
years of age or mother-child pairs; (ii) involved supplementation 
with vitamin D or measured 25(OH)D levels in children or in 
pregnant mothers; (iii) measured neurobehavioural outcomes in 
children including cognitive or motor development, intelligence 
quotient, attention, behaviour, school achievement or language. 
We excluded studies that were in older populations or only 
studied other outcomes apart from neurobehavioural outcomes. 
We also excluded reviews and case studies, commentaries, study 
protocols, reports and letters.
Study selection, data extraction and quality appraisal
First, we screened titles and abstracts of all identified studies 
against the inclusion criteria. We then reviewed full texts for poten-
tially relevant articles to determine eligibility for inclusion. We 
extracted data into an Excel spreadsheet with a list of variables 
determined a priori by the authors. Variables that were extracted 
for the review included the first author’s name and year of pub-
lication, study design, country, sample size, age at vitamin D 
and neurobehavioural assessment, neurobehavioural outcomes 
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and tools used for evaluation, 25(OH)D cut-offs, and findings 
of the study. Study selection and data extraction was carried out 
by two reviewers independently (AMM and RMM) and then 
compared. Disagreements between reviewers were resolved 
through discussion. For this review, we defined severe vitamin D 
deficiency, vitamin D deficiency, insufficiency and sufficiency as 
25(OH)D levels <25 nmol/L, 25–50 nmol/L, 50–75 nmol/L and 
>75 nmol/L respectively according to the Endocrine Society 
Practice Guidelines23.
We used the Cochrane handbook criteria to assess the risk of 
bias for the randomized controlled trial (RCT)24 and the 
Strengthening the Reporting of Observational Studies in 
Epidemiology (STROBE) checklist to assess for the quality of 
observational studies included in the review25.
Synthesis of included articles
The large degree of diversity in the study populations and meth-
ods necessitated qualitative synthesis for the studies. We grouped 
and discussed the findings by each neurobehavioural outcome 
examined and used tables to present a summary of the study 
characteristics and findings. We compared study findings 
based on when 25(OH)D levels were measured, assays used to 
measure 25(OH)D levels, definitions of vitamin D status and 
tools used to assess neurobehavioural outcomes. For consistency, 
we converted all units of 25(OH)D measurements into nmol/L.
Results
Study selection
Our search identified 5,633 articles and a further 18 articles were 
identified from scanning through reference lists of relevant articles 
(Figure 2). We removed 1,557 duplicate articles. After screen-
ing abstracts and titles, we excluded 4,003 articles that were 
irrelevant to our study and retained 91 papers for full review. 
We excluded 29 studies because the outcomes of interest were 
physical growth, psychiatric disorders or infections, eight because 
they assessed coverage of vitamin D supplementation pro-
grammes and two RCTs because the effect of vitamin D status 
Figure 1. Factors influencing vitamin D status in children and potential roles of vitamin D in brain development11–16,20–22.
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Figure 2. PRISMA flow chart showing the selection process for studies included in the review.
on child development was not measured separately from the effects 
of other micronutrients. We excluded one RCT as it evaluated 
the effect of vitamin D supplementation on cognitive development 
in extremely preterm neonates26. We excluded an additional 20 
articles as they were reviews, case studies, commentaries or study 
protocols.
Study characteristics and outcomes
We included one vitamin D supplementation trial and 30 obser-
vational studies published between 2007 and 2019 in this review. 
Of the 30 observational studies, 19 evaluated the effect of mater-
nal vitamin D status during pregnancy and 11 the effect of a 
child’s vitamin D status on neurobehavioural outcomes in chil-
dren. Of the 11 studies in children, three were cohort studies, two 
were case-control studies and six were cross-sectional studies; 19 
studies were carried out in high-income countries and 13 in low 
and middle-income countries. The sample sizes varied across 
the studies, from 45 to 7065 children (Figure 3). The studies 
evaluated a range of neurobehavioural outcomes using a variety 
of assessment tools. In 21 studies, neurobehavioural assessments 
were conducted by psychologists or trained research or clinical 
staff, seven studies relied on caregiver reports, while three stud-
ies did not provide information on assessors. The studies used 
varying definitions for vitamin D status and different assays to 
quantify 25(OH)D levels (Table 1). All five studies that meas-
ured 25(OH)D levels in cord blood did not provide information 
on the sampling procedures. The characteristics and results of the 
included studies are shown in Table 1. The RCT showed a low 
risk of bias (Extended data file 2)18, although the small sample 
size (n=55) is likely to have limited its power and external 
validity. All observational studies adjusted for multiple poten-
tial confounding factors except one study in which it was 
unclear whether they adjusted for any confounders27. Limitations 
of the observational studies included a lack of description about 
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Figure 3. Sample sizes and types of studies included in the review.
loss to follow-up, and many did not report the reasons for non-
participation and the number of participants missing data for each 
variable (Extended data, file 3)18.
Cognitive development
A total of 15 studies, including 19,810 mother-child pairs evaluated 
the effect of vitamin D status during pregnancy on cognitive 
development in children. Of these, four mother-child studies 
(n=6,239) found a beneficial effect of higher maternal 25(OH)D 
levels on cognitive development and 11 studies (n=13,234) reported 
no association. In a large study of 3,896 American mother-child 
pairs, higher maternal 25(OH)D levels were associated with 
higher intelligence quotient (IQ) scores in children at 7 years of 
age28. Likewise, in a study of 1,820 Spanish mother-child pairs, 
maternal 25(OH)D levels >75 nmol/L were associated with 
higher cognitive scores in children aged 11–23 months compared 
to maternal 25(OH)D levels <50 nmol/L29. Another study of 363 
Chinese mother-child pairs reported that cord blood 25(OH)D 
levels between 5.56 and 20.8 nmol/L were associated with 
lower cognitive scores in 16–18 month-old children than levels 
between 39.9 and 51 nmol/L30. Similarly, a study of 160 Chinese 
mother-child pairs found that maternal 25(OH)D levels <50 nmol/L 
were associated with low cognitive scores in six-month-old 
children31.
However, a large study of 7,065 mother-child pairs in the UK 
reported no association between maternal 25(OH)D levels and 
cognition in eight-year-old children32. Other studies in 1,020 
American and 1,244 Chinese mother-child pairs also found no 
association between maternal 25(OH)D levels during pregnancy 
and cognition in children aged two years or below33,44. Two 
mother-child studies in India (n=940) and Vietnam (n=886) 
also found no association between maternal 25(OH)D levels 
during pregnancy and cognition in children aged six months to 
14 years35,36. Similarly, in six other studies of 2,079 mother-child 
pairs, maternal 25(OH)D levels were not associated with cognitive 
development after birth37–42.
Seven observational studies measured both 25(OH)D levels and 
cognitive development in children. One small cross-sectional 
study (n=45) in Egyptian school children reported that 
those with 25(OH)D levels of 37.5–77.5 nmol/L had improved 
cognitive function compared to those with 25(OH)D levels 
<27.5 nmol/L43. However, a cohort study in 401 Indian chil-
dren found no association between vitamin D status at six to 30 
months of age with cognitive development at 12 to 36 months of 
age44. Additionally, two case-control studies of 1,244 children 
with neurodevelopmental disabilities and 670 controls with nor-
mal development in the USA reported no association between 
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vitamin D status and cognitive development at two to nine years of 
age52,53. Likewise, a cross-sectional study of 1,790 American 
adolescents aged 12 to 16.9 years did not find an association with 
cognitive development57. Similarly, two cross-sectional studies, one 
of 1,370 Kuwaiti adolescents aged 11 to 16 years old and another 
of 205 Bangladeshi children aged six to eight months reported 
no association between vitamin D status and cognitive 
development50,54.
Motor development
One small vitamin D supplementation trial in 55 Canadian chil-
dren aged three to six months evaluated the effect of vitamin D 
in doses of 400 international units (IU), 800 IU and 1200 IU on 
gross motor skills. The study did not include a placebo arm. 
They reported that supplementation with 400 IU vitamin D was 
beneficial for gross motor development in infants compared to 
supplementation with 800 or 1200 IU of vitamin D45.
A total of 10 studies including 11,503 mother-child pairs examined 
the association between motor development and vitamin D status. 
In five mother-child studies (n=9,549), high maternal 25(OH)D 
levels were associated with improved motor development; 
however, five studies (n=6,850) found no association. A large 
study of 7,065 mother-child pairs in the UK reported a trend 
of improved gross and fine motor scores in 18–30 month-old 
children with increasing maternal 25(OH)D levels32. Another 
study of 1,820 Spanish mother-child pairs, similarly showed 
that maternal 25(OH)D levels >75 nmol/L were associated with 
higher motor scores in infancy compared to levels <50 nmol/L29. 
A study of 160 Chinese mother-child pairs showed that 
vitamin D deficient (25(OH)D levels <50 nmol/L) moth-
ers were more likely to have children with lower psychomotor 
development scores at six months of age compared to mothers 
without deficiency31. Another study of 141 Indonesian mother-
child pairs reported that maternal 25(OH)D levels <25 nmol/L 
were associated with impaired motor development in children 
at three and 12 months of age37. Interestingly, a study of 363 
Chinese mother-child pairs reported an inverted u-shaped trend 
of association with lower motor scores in toddlers that had cord 
blood 25(OH)D levels between 5.56 and 20.8 nmol/L and 
between 51.3 and 111 nmol/L compared to the reference category 
(levels 31.0 to 39.8 nmol/L)30. However, two large mother-child 
studies in the USA (n=3,896) and China (n=1,244) and 
smaller studies in Vietnam (n=886), Greece (n=487) and 
Australia (n=337) reported no association between 25(OH)D 
levels during pregnancy and motor development in children 
aged between six months to four years28,33,36,40,41.
Five studies assessed both 25(OH)D levels and motor develop-
ment in children. A cross-sectional study among 186 Iranian 
children reported that 25(OH)D levels >75 nmol/L were associ-
ated with improved gross motor ability compared to 25(OH)D 
levels <50 nmol/L at one year of age27. However, a cohort 
study in 401 Indian children reported no association between 
vitamin D status measured at six to 30 months and motor devel-
opment at 12 to 36 months44. Another cohort study in 904 
Indian children found that vitamin D status measured at six months 
and at three to six years was not associated with gross motor 
development at three to six years of age56. Likewise, two 
cross-sectional studies, one in 912 five-year-old Indian children 
and another in 205 Bangladeshi infants aged six to eight months 
reported no association with motor development50,55.
Language development
The association between maternal 25(OH)D levels and language 
development was evaluated in six studies including a total of 
4,128 mother-child pairs. Four studies, including a total of 2,986 
mother-child pairs, reported a positive association between high 
maternal 25(OH)D levels and improved language development, 
while two other studies including 1,142 mother-child pairs reported 
no association. A study of 1,020 American mother-child pairs 
reported that maternal 25(OH)D levels ≥75 nmol/L were positively 
associated with receptive language but not expressive language 
in two-year-old children34. Likewise, a study of 886 Vietnamese 
mother-child pairs reported that six-month-old infants born to 
women with 25(OH)D levels <37.5 nmol/L had lower language 
scores compared to those with 25(OH)D levels ≥75 nmol/L36. 
Similarly, in a study involving 743 mother-child pairs, children 
of mothers with 25(OH)D levels <46 nmol/L were almost two 
times more likely to have language impairment compared to those 
of women with 25(OH)D levels >72 nmol/L at two years of 
age49. In another study of 337 Australian mother-child pairs, higher 
cord blood 25(OH)D levels were associated with an increase 
in mean language scores at 18 months and four years41. 
However, two studies of 1,142 mother-child pairs reported no 
association between vitamin D status and language development 
in children aged five to 14 years35,39. A single cross-sectional study 
in 205 Bangladeshi infants aged six to eight months reported a 
positive association between 25(OH)D levels >50 nmol/L in 
children and language development compared to levels <50 
nmol/L50.
Behavioural development
The association between maternal 25(OH)D levels and behav-
ioural development was evaluated in 11 mother-child studies. 
Four mother-child studies (n=7,770) reported an association 
between high 25(OH)D levels during pregnancy and improved 
behavioural development in children; however, eight stud-
ies (n=10,149) found no association. A large study of 7,065 
mother-child pairs in the UK reported an increasing trend of social 
development scores with increasing maternal 25(OH)D levels in 
children at 42 months of age32. Another study of 487 mother-child 
pairs in Greece reported that maternal 25(OH)D levels 
>50.7 nmol/l were associated with better behavioural scores 
compared to 25(OH)D levels <38.4 nmol/l40. Likewise, a study 
of 218 mother-child pairs in the USA reported that low mater-
nal 25(OH)D levels (unspecified values) were associated with 
impaired behavioural development among white and Hispanic, 
but not black, infants at one to two years of age47. A study of 
2,107 mother-child pairs reported a positive association between 
maternal 25(OH)D levels >75 nmol/L and improved social 
competence scores compared to levels <50 nmol/L; however, 
they found little association between maternal 25(OH)D levels 
and total behavioural problems46. Two large mother-child studies 
in the USA (n=3,896) and China (n=1,244) found no associa-
tion between maternal 25(OH)D levels and behaviour in children 
aged two to 18 years28,33. Two other studies of 1,080 
mother-child pairs in Australia reported no association between 
Page 13 of 27
Wellcome Open Research 2020, 5:28 Last updated: 12 JUN 2020
maternal 25(OH)D levels and behaviour in 18–24 month-old 
children41,49. Likewise, three mother-child studies in Vietnam 
(n=886), Ireland (n=734) and Seychelles (n=202) reported 
no association between maternal 25(OH)D levels and behaviour 
in children aged six months to five years36,38,39.
Three studies measured both 25(OH)D levels and behavioural 
development in children. A cohort study of 254 Ugandan chil-
dren found an association between 25(OH)D levels <50 nmol/L at 
enrollment, at six to 10 years of age, and poor behavioural 
outcomes measured at enrollment, and at six and 12 months after 
enrollment, among children who were perinatally exposed to 
HIV but were uninfected and unexposed HIV negative chil-
dren51. A cross-sectional study of 401 Indian children found that 
children with 25(OH)D levels <25 nmol/L had lower scores on the 
personal-social sub-scale at six to 36 months44, and a cross-
sectional study in 205 Bangladeshi children aged six to eight 
months reported an association between 25(OH)D levels 
<50 nmol/L and impaired parent-reported behaviour50.
School achievement
Two mother-child studies and two cross-sectional studies evalu-
ated the effect of vitamin D status on school achievement. The 
two mother-child studies, including a total of 4,694 mother-child 
pairs, observed no association between maternal vitamin 
D status and children’s educational achievement28,48. The two 
cross-sectional studies reported conflicting findings. A study 
of 45 Egyptian children reported that 25(OH)D levels between 
37.5 and 77.5 nmol/L were associated with improved school 
achievement compared to 25(OH)D levels <27.5 nmol/L43, 
while a study of 1,370 Kuwaiti adolescents reported no 
association between vitamin D status and school achievement54.
Studies that assessed neurobehavioural outcomes during 
infancy
Six observational studies assessed neurobehavioural outcomes 
during infancy and of these studies, five reported associations 
between maternal or child 25(OH)D levels and neurobehavioural 
outcomes, while one study reported no associations. In contrast, 
24 studies assessed neurobehavioural outcomes in children 
above one year of age and of these, 11 studies reported 
associations between maternal or child 25(OH)D levels and neu-
robehavioural outcomes, while 13 studies reported no associations.
Comparing findings based on the timing, assays and cut-
offs for 25(OH)D levels and neuroassessment tools
Six out of eight studies that measured maternal 25(OH)D lev-
els in the 1st or 2nd trimester reported associations with neurobe-
havioural outcomes in contrast to three out of eight studies that 
measured 25(OH)D levels in the 3rd trimester or in cord blood. 
Three out of seven studies that measured 25(OH)D levels in 
infancy and two out five studies that measured levels in chil-
dren above one year reported associations with neurobehavioural 
outcomes (Table 1). The most commonly used assay for measur-
ing 25(OH)D levels was liquid chromatography-tandem mass 
spectroscopy (LC-MS/MS) (Table 1) with four out of 11 studies 
that used LC-MS/MS reporting associations between maternal 
or child 25(OH)D levels and neurobehavioral outcomes, while 
13 out of 20 studies that used other assays reported associations. 
The majority of studies (n=15) defined vitamin D deficiency 
as 25(OH)D levels <50 nmol/L and six of these studies reported 
associations with neurobehavioural outcomes. Six studies 
defined vitamin D deficiency as 25(OH)D levels <30 nmol/L or 
<25 nmol/L and of these two reported associations with neu-
robehavioural outcomes (Table 1). The most common tool used 
to assess neurobehavioural outcomes was the Bayley Scales of 
Infant Development (BSID) and six out of eight studies that used 
the BSID reported associations between 25(OH)D levels and 
neurobehavioural outcomes (Table 1).
Discussion
In this systematic review, we found inconclusive evidence for 
the effects of maternal or child vitamin D status on neurobehav-
ioural outcomes in children below 18 years of age. A small RCT 
(n=55) reported that infants given lower vitamin D doses had 
improved motor development compared to those given higher 
vitamin D doses suggesting that higher doses of vitamin D might 
impair motor development. Similarly, evidence from observa-
tional studies was conflicting. Twelve studies of 17,136 mother-
child pairs and five studies in of 1,091 children reported an 
association between low maternal or child 25(OH)D and 
impaired neurobehavioural outcomes in children. However, 15 
studies of 20,778 mother-child pairs and eight studies of 7,496 
children found no association between vitamin D status and 
neurobehavioural outcomes.
We found conflicting evidence for the effects of vitamin D status 
on cognitive development. Overall, we found little evidence for 
a detrimental effect of low maternal or child 25(OH)D levels 
on cognitive development. Lack of association might be explained 
by the adequate baseline levels of 25(OH)D observed in some 
of the study populations. Of the 17 observational studies 
that reported no association, 11 observed maternal or child 
mean or median (25(OH)D levels >50 nmol/L), while four of the 
five studies that reported an association observed sub-optimal 
25(OH)D levels (mean or median levels <50 nmol/L). Also, it 
is possible that some of the neurodevelopmental assessment 
tools were not sensitive enough to detect subtle effects of 
vitamin D on cognition. For example, Tylavsky et al. suggest 
that the Bailey Scales of Infant Development used in their study 
could have failed to detect small changes in recognition mem-
ory, symbolic play, acuity, or information processing speed34. 
Although there is little evidence in humans, animal and in vitro 
studies suggest that vitamin D influences cognitive develop-
ment58–60. In vitro studies show that vitamin D receptors and cyto-
chrome enzymes responsible for vitamin D metabolism are present 
in the cortex and other parts of the brain involved in cognition11. 
Additionally, vitamin D in its active form (1,25(OH)2D) influ-
ences cytokine production which may affect neurotransmission 
and synaptic plasticity, in turn altering learning processes and 
cognition as observed in rats61.
Similarly, findings for an effect of vitamin D status on motor 
development were mixed. More mother-child studies indicated 
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adverse effects for lower maternal 25(OH)D levels on motor devel-
opment compared to cross-sectional studies in children. Only 
one cross-sectional study reported an association between lower 
25(OH)D levels in children and motor development but these find-
ings were unadjusted for potential confounders27. Three of the 
four studies that reported no association between child vitamin 
D status and motor function used the Ages and Stages Question-
naire-3 to assess gross motor development44,55,56. This tool was 
designed to diagnose children with developmental abnormalities 
and may not be sensitive enough to detect small changes in 
motor function62. How might maternal vitamin D status affect 
motor development? Maternal vitamin D deficiency has been 
associated with congenital rickets with apparent foetal bone 
disease and impaired bone quality postnatally63. One study 
reported an inverted u-shaped association so that both lower 
(5.56 to 20.8 nmol/L) and higher (51.3 to 111 nmol/L) maternal 
25(OH)D levels were associated with impaired motor develop-
ment in children30. This finding is supported by a small vitamin 
D supplementation trial in 55 infants, which found that a lower 
dose of vitamin D supplementation might be more beneficial 
for gross motor function compared to higher doses of vitamin 
D45. However, the findings of this trial may be limited by the lack 
of a control arm that did not receive vitamin D supplementation. 
It is possible that excess levels of vitamin D may result in toxic 
and pro-inflammatory effects which could lead to impaired motor 
development64,65 and that an optimal 25(OH)D level may be 
required. Vitamin D status might also influence motor 
development through its role in neurotransmission through the 
dopaminergic system. Data from animal studies show that vita-
min D deficiency is associated with alterations in the synthesis 
and turnover of dopamine, norepinephrine and dihydroxyphe-
nylacetic acid in rats20,66,67 and ventral midbrain dopaminergic 
neurons have been shown to play a crucial role in the regulation 
of motor processes66.
We found evidence for associations between low vitamin D 
status and impaired language development in four out of six 
mother-child studies. In one study, impairment of language 
development was only observed when 25(OH)D levels fell below 
37.5 nmol/L in late pregnancy, suggesting that language impair-
ment is a feature of advanced vitamin D deficiency rather than 
insufficiency36. However, two mother-child studies (n=1,142) 
reported no association between maternal vitamin D status 
and language scores in adolescence, but these studies did not 
account for the vitamin D status of the adolescents, and it is 
possible that detrimental effects may have been evident ear-
lier in life, but not in adolescence35,39. A possible mechanism 
for the observed association could be that in utero exposure to 
low vitamin D concentrations during the second and third tri-
mesters may affect the development of the perisylvian structures, 
which are responsible for language development in children as 
reported in structural neuroimaging studies21,68. Additionally, 
maternal vitamin D deficiency has been shown to alter the 
brain structure and genes that are involved in neuronal survival 
and speech and language development (brain-derived neuro-
trophic factor (Bdnf) and forkhead box protein P2 (Foxp2) genes, 
respectively) in mice20.
We found mixed evidence for the effect of vitamin D deficiency 
on behaviour in children. Eight of 11 mother-child studies reported 
no association between maternal vitamin D status and behav-
iour. Of these studies, four relied on parent-reported behaviours 
only, which might be prone to bias, and only three relied on 
psychologist assessments or well-validated tools in evaluating 
behaviour. Additionally, it might be difficult to estimate the 
effect of maternal vitamin D status on behavioural outcomes in 
childhood since a wide variety of maternal, environmental and 
genetic risk factors may cause confounding. Animal and in vitro 
studies suggest that vitamin D status might influence behav-
iour possibly via the anti-inflammatory effects of vitamin D, 
which protect against maternal immune activation, which may 
affect foetal brain development and behavioural manifesta-
tions69. Additionally, vitamin D deficiency is associated with 
alterations in the synthesis of serotonin, a neurotransmitter 
that is important for behavioural outcomes70.
There may be many explanations for our findings of inconsist-
ent evidence for the effects of hypovitaminosis D on child devel-
opment. There were substantial differences in study design 
between studies with some assessing maternal and some chil-
dren’s vitamin D status in relation to child development. Studies 
also had different inclusion criteria and definitions for vitamin D 
status and were also adjusted for different confounding variables. 
Serum or plasma 25(OH)D levels were quantified using a vari-
ety of routinely available assays with most studies using the gold 
standard of liquid chromatography–tandem mass spectrometry(LC-
MS/MS). There was little difference in neurobehavioral 
outcomes in studies that used LC-MS/MS and studies that used 
other assays to measure 25(OH)D levels. The lack of standard-
ized assays may result in large inter-method variability and errors 
limiting comparability between studies71. Secondly, vitamin D 
status was measured at varying gestational ages in mothers and 
different ages in the children. Several studies that measured 
maternal 25(OH)D in the 1st or 2nd trimester, rather than the 
3rd trimester or in cord blood, reported associations between 
low maternal 25(OH)D and low developmental scores in the 
children28,29,31,34,49, which might suggest a critical window for the 
impact of low 25(OH)D levels earlier in pregnancy when there 
is rapid brain development72. There was little difference when 
comparing findings between studies that measured 25(OH)D lev-
els during or after infancy. In addition, studies suggest that there 
might be optimal levels of vitamin D required for development 
with higher levels also being associated with impaired develop-
ment30,45. Thirdly, the timing and tools used to assess neurobehav-
ioural outcomes varied markedly between studies. The majority of 
studies that assessed neurobehavioural outcomes during infancy 
reported associations between maternal or child 25(OH)D 
levels and neurobehavioral outcomes compared to fewer than half 
of studies that assessed neurobehavioural outcomes after infancy. 
Putative effects might be more likely to be detected in earlier 
years of life and may also be influenced by 25(OH)D levels through-
out childhood. Most studies used the Bayley Scales of Infant 
Development to assess neurobehavioral outcomes in chil-
dren, with more than half of these studies reporting associations 
between 25(OH)D levels and neurobehavioral outcomes. However, 
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comparisons based on the neuroassessment tools were limited as 
most studies used several tools to assess different neurobehav-
ioural outcomes. Studies that measured 25(OH)D levels during 
pregnancy and child development did not account for the vita-
min D status of children at the time of neuroassessment, which 
may also have influenced neurobehavioural outcomes. The appli-
cation of findings from experimental studies to human beings 
may also be limited. For instance, animal experiments can cre-
ate conditions of extremely low 25(OH)D levels which may 
not normally be found in humans.
We identified two previous systematic reviews and one meta- 
analysis of the effects of maternal vitamin D status on neurobe-
havioural outcomes in children. Consistent with our review, a 
systematic review of maternal micronutrient status (vitamin D, 
B12, iron and folate) and carbohydrate, protein and fat intake 
during pregnancy and cognitive development in childhood found 
limited and conflicting evidence for the effect of vitamin D status 
on cognitive development73. However, of 38 eligible studies, this 
review included only three mother-child studies on vitamin D sta-
tus and cognitive development, also included in our review29,42,49. 
Another systematic review also found contradictory evidence 
for the effect of maternal vitamin D status during pregnancy on 
neurobehavioural outcomes and neuropsychological disor-
ders in children74. This review included only 10 human studies, 
four of which evaluated neuropsychological disorders and six 
neurobehavioural outcomes, but cognition, motor, language 
and behavioural outcomes were not evaluated74. Another sys-
tematic review and meta-analysis of the neurodevelopmental 
effects  of prenatal vitamin D reported an association between 
increased maternal 25(OH)D levels and improved cognition and 
reduced risk of autism and attention deficit and hyperac-
tivity disorder (ADHD)75. Unlike our review, they did not 
include studies that measured vitamin D status of children. 
Additionally, the findings of the meta-analysis may be lim-
ited by the different definitions for vitamin D status used 
across the included studies75.
Strengths and limitations
A key strength of our review is that it was very comprehensive, 
since we searched seven databases without geographic location, 
date or language limitations. We included one randomized con-
trolled trial and observational studies assessing the effects of 
maternal and child vitamin D status on neurobehavioural outcomes. 
Also, we included children up to the age of 18 years, hence cap-
turing child development through to adulthood. There were sev-
eral limitations in this review. We found substantial heterogeneity 
in study populations and study methods including timing of 
vitamin D measurements, definitions for vitamin D status and 
tools used to measure neurobehavioural outcomes which made 
comparison of the studies difficult and precluded a quantitative 
meta-analysis of the studies. However, we did not observe marked 
differences when comparing findings in studies that defined vita-
min D deficiency as 25(OH)D levels <50 nmol/L with those that 
defined vitamin D deficiency as 25(OH)D levels <30 nmol/L or 
<25 nmol/L. There was only one small vitamin D supplementation 
trial and few studies measured 25(OH)D levels in children. We 
identified another small RCT (n=70) in the USA which reported 
no beneficial effect of vitamin D supplementation on cognition 
at two years of age26, but we excluded this study as it included 
extremely preterm neonates, who are at a higher risk of neurodevel-
opmental delays compared to children born at full term76. We also 
found a relatively small number of studies from low-income 
countries. Evidence for the effects of vitamin D deficiency on 
neurobehavioural outcomes from studies in high-income countries 
might not be generalizable to low-income settings, where impaired 
child development may be more common, and confounding 
effects might also differ between these settings. Additionally, 
isolating the effect of vitamin D on neurobehavioural outcomes 
may be limited by confounding factors. We excluded two rand-
omized controlled trials that did not evaluate the effect of vitamin 
D separately from other micronutrients77,78. Moreover, although 
most of the observational studies adjusted for measured confound-
ers, evidence may still be subject to residual confounding from 
unmeasured factors, such as dietary intake of other micro 
and macronutrients.
Conclusion
Evidence as to whether prenatal or childhood vitamin D sta-
tus affects neurobehavioural outcomes in children is limited and 
inconsistent and further investigation is warranted. For instance, 
standardized cut-offs for assessing vitamin D deficiency, as 
well as well-validated and standardized methods of assessing 
neurobehavioural outcomes would be useful to allow compari-
son among studies globally. Well-powered randomized controlled 
trials are required to determine whether vitamin D is beneficial 
for brain development in children and for optimal dosage and 
timing of vitamin D supplementation.
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Title: Currently suggestive rather than descriptive - Suggest amendment to: "Inconclusive
associations between vitamin D status during pregnancy or at birth and neuro-behavioural
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Page 21 of 27
Wellcome Open Research 2020, 5:28 Last updated: 12 JUN 2020
 Is the statistical analysis and its interpretation appropriate?
Yes
Are the conclusions drawn adequately supported by the results presented in the review?
Yes
 No competing interests were disclosed.Competing Interests:
Reviewer Expertise: Nutrition; Vitamin D; Maternal & Child nutrition and development.
I confirm that I have read this submission and believe that I have an appropriate level of
expertise to confirm that it is of an acceptable scientific standard.
Author Response 03 Jun 2020
, KEMRI-Wellcome Trust Research Programme, Kilifi, KenyaSarah Atkinson
We thank the reviewer for their insightful comments. 
The Salas paper on preterm infants should not be included as preterm infants are a
different and high-risk subgroup from a developmental perspective. 
Response: As noted, extremely preterm neonates are at a higher risk of neurodevelopmental
delays compared to children born at full term. We have now excluded the Salas paper as
suggested and mentioned it briefly in the Results and Discussion indicating the reason for
exclusion as follows:
Results under ‘Study Selection’: “We excluded one RCT as it evaluated the effect of vitamin D
supplementation on cognitive development in extremely preterm neonates [1].”
Discussion under ‘Strengths and limitations’: “We identified another small RCT (n=70) in the USA
which reported no beneficial effect of vitamin D supplementation on cognition at two years of age,
but we excluded this study as it included extremely preterm neonates, who are at a high risk of
neurodevelopmental delays compared to children born at full term [3].”
We have updated Figures 2 and 3 to reflect this exclusion.
 
Although the authors correctly point out the deficits in the trial data, I thought that the
discussion could have appraised the evidence basis more from the prospective cohorts
from a vitamin D perspective; for example, were gold standard methods of 25(OH)D
analysis used? Were appropriate methods used for cord blood sampling and analysis? 
Response: Thank you. We agree that appraisal of the methods used to quantify 25(OH)D levels is
important. We have now included the different assays used to quantify serum or plasma 25(OH)D
levels in Table 1 and in the Results and Discussion sections as follows:
 “Results under ‘Study characteristics and outcomes’: The studies used varying definitions for
vitamin D status and different assays to quantify 25(OH)D levels (Table 1). All five studies that
measured 25(OH)D levels in cord blood did not provide information on the sampling procedures.” 
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 Results under ‘Comparing findings based on the timing, assays and cut-offs for 25(OH)D levels
and neuroassessment tools.: “The most commonly used assay for measuring 25(OH)D levels was
liquid chromatography-tandem mass spectroscopy (LC-MS/MS) (Table 1) with four out of 11
studies that used LC-MS/MS reporting associations between maternal or child 25(OH)D levels and
neurobehavioral outcomes, while 13 out of 20 studies that used other assays reported associations
.” 
Discussion, Paragraph 6: “Serum or plasma 25(OH)D levels were quantified using a variety of
routinely available assays with most studies using the gold standard of liquid
chromatography–tandem mass spectrometry (LC-MS/MS). There was little difference in
neurobehavioral outcomes in studies that used LC-MS/MS and studies that used other assays to
measure 25(OH)D levels. The lack of standardized assays may result in large inter-method
variability and errors limiting comparability between studies [2].” 
 
Could some sensitivity analysis have been conducted on the basis of 25(OH)D
concentrations reported given the widely variant definitions of "vitamin D deficiency"? 
Response: We thank the reviewer for this comment and note that a main limitation of the review is
the high level of heterogeneity in the studies which precluded a meta-analysis and formal
sensitivity analyses. We have added the following information: 
 “Methods under ‘Synthesis of included articles’: We compared study findings based on when
25(OH)D levels were measured, assays used to measure 25(OH)D levels, definitions of vitamin D
status and tools used to assess neurobehavioural outcomes.”
Results under ‘Comparing findings based on the timing, assays and cut-offs for 25(OH)D levels
and neuroassessment tools’: “Six out of eight studies that measured maternal 25(OH)D levels in
the 1  or 2  trimester reported associations with neurobehavioural outcomes in contrast to three
out of eight studies that measured 25(OH)D levels in the 3  trimester or in cord blood. Three out of
seven studies that measured 25(OH)D levels in infancy and two out five studies that measured
levels in children above one year reported associations with neurobehavioural outcomes (Table 1).
The most commonly used assay for measuring 25(OH)D levels was liquid chromatography-tandem
mass spectroscopy (LC-MS/MS) (Table 1) with four out of 11 studies that used LC-MS/MS
reporting associations between maternal or child 25(OH)D levels and neurobehavioral outcomes,
while 13 out of 20 studies that used other assays reported associations. The majority of studies
(n=15) defined vitamin D deficiency as 25(OH)D levels <50 nmol/L and six of these studies
reported associations with neurobehavioural  outcomes. Six studies defined vitamin D deficiency
as 25(OH)D levels <30 nmol/L or <25 nmol/L and of these two reported associations with
neurobehavioural outcomes  (Table 1). The most common tool used to assess neurobehavioural
outcomes was the Bayley Scales of Infant Development (BSID) and six out of eight studies that
used the BSID reported associations between 25(OH)D levels and neurobehavioural outcomes
(Table 1).”
Discussion under ‘Strengths and limitations’: “We found substantial heterogeneity in study
populations and study methods including timing of vitamin D measurements, definitions for vitamin
D status and tools used to measure neurobehavioural outcomes which made comparison of the
studies difficult and precluded a quantitative meta-analysis of the studies. However, we did not
observe marked differences when comparing findings in studies that defined vitamin D deficiency
as 25(OH)D levels <50 nmol/L with those that defined vitamin D deficiency as 25(OH)D levels <30
st nd
rd
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 as 25(OH)D levels <50 nmol/L with those that defined vitamin D deficiency as 25(OH)D levels <30
nmol/L or <25 nmol/L.”
Discussion Paragraph 6: “Serum or plasma 25(OH)D levels were quantified using a variety of
routinely available assays with most studies using the gold standard of liquid
chromatography–tandem mass spectrometry (LC-MS/MS). There was little difference in
neurobehavioral outcomes in studies that used LC-MS/MS and studies that used other assays to
measure 25(OH)D levels. The lack of standardized assays may result in large inter-method
variability and errors limiting comparability between studies [2]. Secondly, vitamin D status was
measured at varying gestational ages in mothers and different ages in the children. Several studies
 that measured maternal 25(OH)D in the 1  or 2   trimester, rather than the 3   trimester or in cord
blood, reported an association between low maternal 25(OH)D and low developmental scores in
 the children ,which might suggest a critical window for the impact of low 25(OH)D
levels earlier in pregnancy when there is rapid brain development [71]. There was little difference
when comparing findings between studies that measured 25(OH)D levels during or after infancy. In
addition, studies suggest that there might be optimal levels of vitamin D required for development
 with higher levels also being associated with impaired development . Thirdly, the timing and
tools used to assess neurobehavioural outcomes varied markedly between studies. The majority of
studies that assessed neurobehavioural outcomes during infancy reported associations between
25(OH)D levels and neurobehavioral outcomes compared to fewer than half of studies that
assessed neurobehavioural outcomes after infancy. Putative effects might be more likely to be
detected in earlier years of life and may also be influenced by 25(OH)D levels throughout
childhood. Most studies used the Bayley Scales of Infant Development to assess neurobehavioral
outcomes in children, however, comparisons based on the tools were limited as most studies used
several tools to assess different neurobehavioural outcomes.”
 
Were the developmental assessments led by clinical psychologists within a MDT? 
Response: We have now included a summary of the teams that assessed neurobehavioural
outcomes in the studies in the sub-section ‘Study characteristics and outcomes’ in the Results
section as follows:
Results under ‘Study characteristics and outcomes’: “In 21 studies, neurobehavioural assessments
were conducted by psychologists or trained research or clinical staff, seven studies relied on
caregiver reports, while three studies did not provide information on assessors.”
 
Title: Currently suggestive rather than descriptive - Suggest amendment to: "Inconclusive
associations between vitamin D status during pregnancy or at birth and
 neuro-behavioural outcomes in children: a systematic review."
Response: Thank you for the suggestion. However, we note that our review includes one
randomised controlled trial and includes studies where vitamin D status was measured in
childhood and the suggested title may not be inclusive of all studies. 
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Thank you for your comprehensive responses. Approved. 
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This MS focuses on the impact of vitamin D upon child development, using a systematic approach.
Overall comments:
The MS is well written and easy to follow. The objectives are clear and the conclusions well
presented.
 
The authors have used we/our throughout rather than third person or indirect language.
Specific comments:
The first paragraphs of the Methods and Results sections don't have subheadings - these should
be added.
 
The authors used very broad inclusion criteria, for instance including children to age 18 years. A
more limited focus, for instance on infancy or the preschool years, may have provided more
emphasis on key early aspects of development.
 
Further, vitamin D may be hard to consider as an isolated effect (separate to other micro or
macronutrient factors). Was this considered?
Are the rationale for, and objectives of, the Systematic Review clearly stated?
Yes
Are sufficient details of the methods and analysis provided to allow replication by others?
Yes
Is the statistical analysis and its interpretation appropriate?
I cannot comment. A qualified statistician is required.
Are the conclusions drawn adequately supported by the results presented in the review?
Yes
 No competing interests were disclosed.Competing Interests:
Page 25 of 27
Wellcome Open Research 2020, 5:28 Last updated: 12 JUN 2020
  No competing interests were disclosed.Competing Interests:
Reviewer Expertise: Paediatric gastroenterology, with focus on IBD and the impact of vitamin D
I confirm that I have read this submission and believe that I have an appropriate level of
expertise to confirm that it is of an acceptable scientific standard.
Author Response 03 Jun 2020
, KEMRI-Wellcome Trust Research Programme, Kilifi, KenyaSarah Atkinson
We thank the reviewer for his helpful comments, which we have addressed point-by-point below:
 
The first paragraphs of the Methods and Results sections don't have subheadings - these
 should be added.
Response: We have added the subheadings ‘Reporting guidelines’ in the Methods section and
‘Study selection’ in the Results section.
 
The authors used very broad inclusion criteria, for instance including children to age 18
years. A more limited focus, for instance on infancy or the preschool years, may have
 provided more emphasis on key early aspects of development. 
Response: We agree that the early years of life are particularly crucial for brain development. We
have included a subsection ‘Studies that assessed neurobehavioural outcomes in infancy’ in the
Results section comparing studies that assessed development during infancy and those that
assessed development in older children and have also updated the Discussion accordingly as
follows:
Results, under ‘Studies that assessed neurobehavioural outcomes in infancy’: “Six observational
studies assessed neurobehavioural outcomes during infancy and of these studies, five reported
associations between maternal or child 25(OH)D levels and neurobehavioural outcomes, while one
study reported no associations. In contrast, 24 studies assessed neurobehavioural outcomes in
children above one year of age and of these, 11 studies reported associations between maternal or
child 25(OH)D levels and neurobehavioural outcomes, while 13 studies reported no associations.”
Discussion Paragraph 6: “Thirdly, the timing and tools used to assess neurobehavioural outcomes
varied markedly between studies. The majority of studies that assessed neurobehavioural
outcomes during infancy reported associations between maternal or child 25(OH)D levels and
neurobehavioral outcomes compared to fewer than half of studies that assessed neurobehavioural
outcomes after infancy. Putative effects might be more likely to be detected in earlier years of life
and may also be influenced by 25(OH)D levels throughout childhood.”
 
Further, vitamin D may be hard to consider as an isolated effect (separate to other micro
or macronutrient factors). Was this considered? 
Response: We agree that the effects of vitamin D on development are possibly confounded by
other factors including the effects of other micro and macronutrients. We excluded two RCTs from
the systematic review as they did not evaluate the effect of vitamin D on neurobehavioural
outcomes in children separately from other micronutrients and have also now discussed this as a
potential limitation of the study as follows: 
Page 26 of 27
Wellcome Open Research 2020, 5:28 Last updated: 12 JUN 2020
 Results under ‘Study Selection’: “We excluded 29 studies because the outcomes of interest were
physical growth, psychiatric disorders or infections, eight because they assessed coverage of
vitamin D supplementation programmes and two RCTs because the effect of vitamin D status on
child development was not measured separately from the effects of other micronutrients.”
Discussion under ‘Strengths and limitations’: “Additionally, isolating the effect of vitamin D on
neurobehavioural outcomes may be limited by confounding factors. We excluded two randomised
controlled trials that did not evaluate the effect of vitamin D separately from other micronutrients [4,
5]. Moreover, although most of the observational studies adjusted for measured confounders,
evidence may still be subject to residual confounding from unmeasured factors, such as dietary
intake of other micro and macronutrients.”
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